Elucid Vivo provides clinical solutions based on histology & machine learning. We provide solutions for lipid rich necrotic core, atherosclerotic plaque, CTA plaque analysis, risk of heart attack, and stroke.
Location: United States
Employees: 51-200
Total raised: $162M
Investors 4
| Date | Name | Website |
| 02.06.2022 | BlueStone ... | bluestonev... |
| - | Biovision ... | biovision.... |
| - | Angel Phys... | angelphysi... |
| - | Bioverge | ventures.b... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 03.09.2026 | Series D | $55M | - |
| 10.11.2023 | Series C | $80M | - |
| 23.06.2022 | Series B | $27M | - |
Mentions in press and media 15
| Date | Title | Description |
| 09.09.2026 | Elucid Secures $55M to Revolutionize Heart Diagnostics with AI | Elucid, a Boston-based medtech innovator, just secured $55M in an oversubscribed Series D funding. Total capital now reaches $185M. The company pioneers AI-powered software for precision cardiovascular diagnosis and treatment. Funds will ac... |
| 03.09.2026 | Elucid Scores $55M Series D Round | BOSTON, MA, Elucid has announced the raise of $55 million in an oversubscribed Series D financing. >> Click here for more funding data on Elucid >> To export Elucid funding data to PDF and Excel, click here Elucid, a medical te... |
| 03.09.2026 | Venture Capital & Startup Funding Roundup, September 3, 2026: Base10 Partners, Gradient Ventures, Point72, Y Combinator & More | Today’s funding narrative reinforces that investors are targeting AI-driven solutions across diverse sectors rather than generic “new AI” startups. Major new rounds span from space manufacturing in New Zealand to AI-augmented medical diagno... |
| 02.09.2026 | Elucid Raises $55M in Seires D Funding | Elucid, a Boston, MA-based provider of AI-powered, clinically validated software to advance precision diagnosis and treatment of cardiovascular disease, raised $55M in Series D funding. Backers included IAG Capital Partners, Elevage Medical... |
| 02.09.2026 | Elucid Raises $55M to Expand AI Cardiovascular Diagnostics | Elucid Raises $55M Series D Funding Boston-based medical technology company Elucid has raised $55 million in fresh funding. The company secured the capital through an oversubscribed Series D financing round. The round brings its total fundi... |
| 02.09.2026 | Elucid Raises $55M to Expand Non-Invasive Cardiovascular Diagnostic Platform | What You Should Know Boston-based cardiovascular medtech innovator Elucid closed an oversubscribed $55M Series D financing round, bringing its cumulative funding to approximately $185M. The round features participation from a new major, pub... |
| 02.09.2026 | Critical Materials Group Raises $10.3M in Seed Funding | Critical Materials Group, an Austin, TX-based provider of a modular energetics production platform, raised $10.3M in Seed funding. The round was led by Overmatch Ventures with participation from Victory Six Advisors and Fulcrum Ventures. Th... |
| 02.09.2026 | HiddenLayer Raises $100M to Expand AI Security Platform | HiddenLayer Raises $100M Series B Funding AI security company HiddenLayer has raised $100 million in a Series B financing round. Delta-v Capital led the round. Ten Eleven Ventures, Morgan Stanley, M12 and Booz Allen Ventures also participat... |
| 13.11.2023 | Elucid collects $80M for AI-powered mapping of blocked arteries | The cardiovascular imaging company Elucid has made it clear they mean to deliver on their promise of artificial intelligence-powered exams to chart the insides of blocked arteries. And now they’ve raised $80 million to do so. Financially sp... |
| 10.11.2023 | Elucid Raises $80M to Drive Commercialization of AI-powered Cardiovascular Diagnostic Tools | What You Should Know: – Elucid, a medical technology company providing AI-powered imaging analysis software to assess cardiovascular disease, has raised $80M in Series C funding led by Elevage Medical Technologies, with additional participa... |
Show more